Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

The heart matters in diabetes: 10-Year outcomes of peripheral artery disease.

Mueller T, Hinterreiter F, Poelz W, Haltmayer M, Dieplinger B.

SAGE Open Med. 2017 Nov 13;5:2050312117740988. doi: 10.1177/2050312117740988. eCollection 2017.

2.

Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure.

Mueller T, Gegenhuber A, Leitner I, Poelz W, Haltmayer M, Dieplinger B.

Clin Chim Acta. 2016 Dec 1;463:158-164. doi: 10.1016/j.cca.2016.10.034. Epub 2016 Oct 29.

3.

Interleukin 6, galectin 3, growth differentiation factor 15, and soluble ST2 for mortality prediction in critically ill patients.

Dieplinger B, Egger M, Leitner I, Firlinger F, Poelz W, Lenz K, Haltmayer M, Mueller T.

J Crit Care. 2016 Aug;34:38-45. doi: 10.1016/j.jcrc.2016.03.020. Epub 2016 Mar 30.

4.

Mortality rates at 10 years are higher in diabetic than in non-diabetic patients with chronic lower extremity peripheral arterial disease.

Mueller T, Hinterreiter F, Poelz W, Haltmayer M, Dieplinger B.

Vasc Med. 2016 Oct;21(5):445-452. Epub 2016 Apr 11.

5.

Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes.

Mueller T, Hinterreiter F, Luft C, Poelz W, Haltmayer M, Dieplinger B.

J Vasc Surg. 2014 May;59(5):1291-9. doi: 10.1016/j.jvs.2013.11.063. Epub 2014 Jan 3.

6.

Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma.

Dieplinger B, Egger M, Gabriel C, Poelz W, Morandell E, Seeber B, Kronenberg F, Haltmayer M, Mueller T, Dieplinger H.

Clin Chim Acta. 2013 Oct 21;425:236-41. doi: 10.1016/j.cca.2013.08.016. Epub 2013 Aug 24.

7.

Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit - The Linz Intensive Care Unit (LICU) study.

Dieplinger B, Egger M, Koehler W, Firlinger F, Poelz W, Lenz K, Haltmayer M, Mueller T.

Clin Chim Acta. 2012 Mar 22;413(5-6):587-93. doi: 10.1016/j.cca.2011.11.028. Epub 2011 Dec 6.

PMID:
22155704
8.

Soluble ST2 is not independently associated with androgen and estrogen status in healthy males and females.

Dieplinger B, Egger M, Poelz W, Gabriel C, Haltmayer M, Mueller T.

Clin Chem Lab Med. 2011 Sep;49(9):1515-8. doi: 10.1515/CCLM.2011.239. Epub 2011 Jun 10.

PMID:
21663467
9.

Long-term stability of soluble ST2 in frozen plasma samples.

Dieplinger B, Egger M, Poelz W, Haltmayer M, Mueller T.

Clin Biochem. 2010 Sep;43(13-14):1169-70. doi: 10.1016/j.clinbiochem.2010.05.019. Epub 2010 Jun 8.

PMID:
20534378
10.

Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department.

Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T.

Clin Biochem. 2010 Jun;43(9):714-9. doi: 10.1016/j.clinbiochem.2010.02.002. Epub 2010 Feb 11.

PMID:
20153308
11.

Pregnancy-associated plasma protein-A as a marker for long-term mortality in patients with peripheral atherosclerosis: inconclusive findings from the Linz Peripheral Arterial Disease (LIPAD) study.

Mueller T, Dieplinger B, Forstner T, Poelz W, Haltmayer M.

Clin Chem Lab Med. 2010 Apr;48(4):537-42. doi: 10.1515/CCLM.2010.103.

PMID:
20148724
12.

Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay.

Dieplinger B, Januzzi JL Jr, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T.

Clin Chim Acta. 2009 Nov;409(1-2):33-40. doi: 10.1016/j.cca.2009.08.010. Epub 2009 Aug 20.

PMID:
19699192
13.

Value of adiponectin as predictor of 5-year all-cause mortality in patients with symptomatic peripheral arterial disease: results from the Linz Peripheral Arterial Disease (LIPAD) study.

Dieplinger B, Haltmayer M, Poelz W, Mueller T.

Clin Chim Acta. 2009 Oct;408(1-2):87-91. doi: 10.1016/j.cca.2009.07.014. Epub 2009 Jul 30.

PMID:
19646980
14.

Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure.

Dieplinger B, Gegenhuber A, Poelz W, Haltmayer M, Mueller T.

Clin Biochem. 2009 Jul;42(10-11):1190-3. doi: 10.1016/j.clinbiochem.2009.02.023. Epub 2009 Mar 6.

PMID:
19272369
15.

Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure.

Dieplinger B, Gegenhuber A, Struck J, Poelz W, Langsteger W, Haltmayer M, Mueller T.

Clin Chim Acta. 2009 Feb;400(1-2):91-6. doi: 10.1016/j.cca.2008.10.012. Epub 2008 Oct 29.

PMID:
19000665
16.

Amino-terminal pro-B-type natriuretic peptide as predictor of mortality in patients with symptomatic peripheral arterial disease: 5-year follow-up data from the Linz Peripheral Arterial Disease Study.

Mueller T, Dieplinger B, Poelz W, Endler G, Wagner OF, Haltmayer M.

Clin Chem. 2009 Jan;55(1):68-77. doi: 10.1373/clinchem.2008.108753. Epub 2008 Nov 6.

17.

Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease.

Mueller T, Dieplinger B, Poelz W, Haltmayer M.

Clin Appl Thromb Hemost. 2009 Dec;15(6):652-9. doi: 10.1177/1076029608322547. Epub 2008 Sep 19.

PMID:
18805846
18.

Influence of hydroxyethyl starch (6% HES 130/0.4) administration on hematology and clinical chemistry parameters.

Mueller T, Schimetta W, Dieplinger B, Loeffler P, Rehm M, Kreimeier U, Poelz W, Haltmayer M.

Clin Chem Lab Med. 2008;46(4):558-62. doi: 10.1515/CCLM.2008.107.

PMID:
18605936
19.

Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure.

Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M.

Clin Chem. 2008 Apr;54(4):752-6. doi: 10.1373/clinchem.2007.096560.

20.

Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease.

Dieplinger B, Lingenhel A, Baumgartner N, Poelz W, Dieplinger H, Haltmayer M, Kronenberg F, Mueller T.

Clin Chem. 2007 Jul;53(7):1298-305. Epub 2007 May 24.

21.
22.
23.

Association of adiponectin and amino terminal proBNP in peripheral arterial disease.

Dieplinger B, Poelz W, Haltmayer M, Mueller T.

Clin Chim Acta. 2007 Feb;377(1-2):192-7. Epub 2006 Sep 30.

PMID:
17112494
24.

Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease.

Dieplinger B, Poelz W, Haltmayer M, Mueller T.

Clin Chem Lab Med. 2006;44(7):830-3.

PMID:
16776628
25.
26.

B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure.

Gegenhuber A, Mueller T, Dieplinger B, Poelz W, Pacher R, Haltmayer M.

Clin Chim Acta. 2006 Aug;370(1-2):174-9. Epub 2006 Mar 6.

PMID:
16600203
27.

Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP.

Gegenhuber A, Struck J, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T.

Clin Chem. 2006 May;52(5):827-31. Epub 2006 Mar 16.

28.
29.

Plasma B-type natriuretic peptide in patients with pleural effusions: preliminary observations.

Gegenhuber A, Mueller T, Dieplinger B, Lenz K, Poelz W, Haltmayer M.

Chest. 2005 Aug;128(2):1003-9. Erratum in: Chest. 2006 Jan;129(1):216. Haltmayers, Meinhard [corrected to Haltmayer, Meinhard].

PMID:
16100199
30.

Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study.

Mueller T, Marschon R, Dieplinger B, Haidinger D, Gegenhuber A, Poelz W, Webersinke G, Haltmayer M.

J Vasc Surg. 2005 May;41(5):808-15.

31.
32.

Equipoise, design bias and randomized controlled trials: the elusive ethics of new drugs--a comment.

Schimetta W, Poelz G, Poelz W, Haring HP, Aichner F.

Arthritis Res Ther. 2004 Nov 23;7(1):E2. No abstract available.

33.

Serum total 8-iso-prostaglandin F2alpha: a new and independent predictor of peripheral arterial disease.

Mueller T, Dieplinger B, Gegenhuber A, Haidinger D, Schmid N, Roth N, Ebner F, Landl M, Poelz W, Haltmayer M.

J Vasc Surg. 2004 Oct;40(4):768-73.

34.

Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples.

Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M.

Clin Chem Lab Med. 2004;42(8):942-4.

PMID:
15387447
35.

Hyperhomocysteinemia and severity of peripheral vascular disease: a rebuttal.

Haltmayer M, Mueller T, Poelz W.

J Thromb Haemost. 2004 Jul;2(7):1212-3; author reply 1214. No abstract available.

36.

Preliminary evaluation of the AxSYM B-type natriuretic peptide (BNP) assay and comparison with the ADVIA Centaur BNP assay.

Mueller T, Gegenhuber A, Poelz W, Haltmayer M.

Clin Chem. 2004 Jun;50(6):1104-6. No abstract available.

37.

Comparison of the automated AxSYM and ADVIA centaur immunoassays for homocysteine determination.

Haltmayer M, Mueller T, Gegenhuber A, Poelz W.

Clin Lab. 2004;50(3-4):175-80.

PMID:
15074472
39.

Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease.

Mueller T, Gegenhuber A, Poelz W, Haltmayer M.

Clin Chim Acta. 2004 Mar;341(1-2):41-8.

PMID:
14967157
40.

Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure.

Gegenhuber A, Mueller T, Firlinger F, Lenz K, Poelz W, Haltmayer M.

Clin Chem. 2004 Feb;50(2):454-6. No abstract available.

41.

Measuring blood homocysteine levels in stroke patients.

Haltmayer M, Mueller T, Poelz W.

Med Sci Monit. 2003 Aug;9(8):LE19. No abstract available.

PMID:
14518504
43.

Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease.

Mueller T, Haltmayer M, Poelz W, Haidinger D.

Vasc Endovascular Surg. 2003 Mar-Apr;37(2):117-23.

PMID:
12669143
44.

Relation between homocysteine and non-fatal stroke in peripheral arterial disease.

Haltmayer M, Mueller T, Lange W, Luft C, Hainzl A, Poelz W, Haidinger D.

Eur J Neurol. 2002 Nov;9(6):609-14.

PMID:
12453076
45.

Erythrocyte mean corpuscular volume associated with the anatomical distribution in peripheral arterial disease.

Mueller T, Luft C, Haidinger D, Poelz W, Haltmayer M.

Vasa. 2002 May;31(2):81-5.

PMID:
12099149
46.

Erythrocyte mean corpuscular volume associated with severity of peripheral arterial disease: an angiographic evaluation.

Haltmayer M, Mueller T, Luft C, Poelz W, Haidinger D.

Ann Vasc Surg. 2002 Jul;16(4):474-9. Epub 2002 Jun 27.

PMID:
12085125
47.

Erythrocyte mean cellular volume and its relation to serum homocysteine, vitamin B12 and folate.

Haltmayer M, Mueller T, Poelz W.

Acta Med Austriaca. 2002;29(2):57-60.

PMID:
12050947
48.

Total serum homocysteine--a predictor of extracranial carotid artery stenosis in male patients with symptomatic peripheral arterial disease.

Mueller T, Furtmueller B, Aigelsdorfer J, Luft C, Poelz W, Haltmayer M.

Vasc Med. 2001;6(3):163-7.

PMID:
11789971
49.

Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease.

Haltmayer M, Mueller T, Horvath W, Luft C, Poelz W, Haidinger D.

Int Angiol. 2001 Sep;20(3):200-7.

PMID:
11573053
50.

Association between erythrocyte mean corpuscular volume and peripheral arterial disease in male subjects: a case control study.

Mueller T, Haidinger D, Luft C, Horvath W, Poelz W, Haltmayer M.

Angiology. 2001 Sep;52(9):605-13.

PMID:
11570659

Supplemental Content

Support Center